Pharma-Bio Serv, Inc (PBSV) Fair Value & Analysis
Healthcare · US · Market cap $13.1M
Pharma-Bio Serv, Inc
PBSV · US
Fair value as of: Jul 25, 2026
From 4 valuation models · updated 16 days ago
Share price +1.8% over the past month.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.1700). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
60‑month range $0.1942 – $1.26 · fair‑value band $0.1400 – $0.1700 · the $0.5800 price screens above the $0.1500 fair value. Dashed = 300-day average. As of Jul 25, 2026.
Analysis
Pharma-Bio Serv, Inc (PBSV) currently trades at $0.5800, while our model-based Fair Value estimate is $0.1500, implying the stock looks roughly 74.1% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Pharma-Bio Serv, Inc generated revenue of $9.1M at a net margin of 0.7%. Revenue grew 11.8% year over year. It earns a return on equity of 0.6%. Fundamentals as of Jul 25, 2026
Our scenario range runs from $0.1400 (bear case) to $0.1700 (bull case); at $0.5800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 49% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -74%, PBSV screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Dividend Discount ($0.5600) versus DCF Models ($0.1700). Highest evidence: Gordon GGM (70).
Notify me when PBSV reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 69
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.
Full company description
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support. It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharma-Bio Serv, Inc reported revenue of $9.0M in FY2025 versus $20.1M in FY2021, a compound −18.2%/yr. Reported net income was −$100K in FY2025.
PBSV screens 74% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Pharma-Bio Serv, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharma-Bio Serv, Inc (PBSV) overvalued or undervalued?
What is the fair value of PBSV?
What is the quality score of PBSV?
What is the revenue of Pharma-Bio Serv, Inc (PBSV)?
What is the net profit margin of PBSV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharma-Bio Serv, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.